Background. At present it is unclear which dose and consecutive blood levels of cyclosporine A (CsA) are optimal with respect to immunosuppressive efficacy and drug specific side effects at the level of individual patients. Several pharmacodynamic measures of CsA effects have been proposed, but have not become clinical routine yet. Besides the lack of practicability, the biological relevance of these assays has not been determined so far. Methods. Residual expression of nuclear factor of activated T-cells (NFAT)-regulated genes two hours after drug intake was used as molecular pharmacodynamic marker to assess CsA effects on lymphocytes and correlated with the frequency of recurrent infections and malignancies in patients with five or more years of follow-up posttransplantation. Results. Recurrent infectious complications were observed in 44% and malignancies in 20% of the 133 patients studied. Patients with a strong suppression of NFAT-regulated genes by CsA-as judged by a residual level of transcription of less than 15% after drug intake-develop more frequent infections (53% vs. 29%; Pϭ0.005) and malignancies (22% vs. 4%; Pϭ0.002). The lack of correlation between the incidence of these complications and CsA blood concentration might point to the interindividual differences in the sensitivity towards calcineurin inhibition. Conclusion. The data presented here reveal a clear relation between the frequency of infectious and malignant complications and the degree of suppression of NFAT-regulated genes by CsA in transplanted patients. Therefore, pharmacodynamic monitoring of CsA efficacy in transplanted patients might be a useful tool to adjust immunosuppressive therapy in individual patients.
C yclosporine A (CsA) is the most commonly used immunosuppressive drug in renal transplantation. With the introduction of calcineurin inhibitors, long-term allograft survival has significantly improved (1), primarily by reduction of acute rejection episodes. However, rational means to balance both the benefits and side effects of CsA treatment are not sufficiently established yet (2, 3) .
One reason for that is a significant inter-and intraindividual variation of CsA absorption and its narrow therapeutic window (4) . Assessment of CsA dosing is primarily performed by blood trough levels, pharmacokinetics such as measurement of two-hour peak levels, or by various area under the curve assessments (AUC, 4 to 12 hr). For the majority of patients, trough level drug monitoring seem to be adequate, but it remains unclear at which dose an optimal degree of immunosuppression is achieved in individual patients. For example, CsA trough levels poorly correlate with the frequency of acute rejection episodes (5) . Some recent studies showed a better correlation of CsA peak levels (as a marker of total CsA exposure) with adequate immunosuppression (6, 7) ; in other studies, CsA two-hour levels did not predict rejection or toxicity (8) . Measurement of the total drug exposure as AUC for four hours after CsA uptake was suggested to be the best method for assessing the variation of CsA absorption and risk of acute rejection or drug toxicity (9) . However, all these mentioned CsA measurements are unable to predict and monitor the biological effects of CsA. Several approaches have been undertaken to measure the biological consequences of CsA-based immunosuppression (10) . Dosing of CsA according to the molecular effect of the drug on its target cells could improve allograft survival and at the same time increase drug safety. For this purpose, both the inhibition of the primary target of CsA-the phosphatase calcineurin-and its consequence the inhibition of nuclear factor of activated T-cells (NFAT)-regulated cytokines such as interleukin-2 (IL-2) were evaluated as pharmacodynamic measures for the effects of CsA (11) (12) (13) .
Recently we described a reliable, precise, and robust whole blood assay based on the measurement of the expression of three NFAT-regulated genes (IL-2, interferon [IFN]-␥, and granulocyte-macrophage colony stimulating factor [GM-CSF]) in phorbol myristate acetate (PMA)/ionomycin stimulated lymphocytes before and 2 hr after CsA intake (14, 15) . The inhibition of genes in this assay reflects calcineurin inhibition and is independent from other commonly used immunosuppressive drugs. In order to validate this assay as a new molecular marker for the degree of immunosuppression in individual patients, we correlated the residual expression of NFAT-regulated genes with the frequency of recurrent infections and malignancies in patients with five or more years of follow-up posttransplantation.
PATIENTS AND METHODS

Patient's Characteristics
The study was approved by the local ethical committee and informed consent was obtained from all patients. All stable renal transplant patients on CsA therapy of the renal transplant outpatient clinic of the Department of Nephrology of the University of Heidelberg, Germany, who met the following inclusion criteria, were included from August 2002 to December 2005. Inclusion criteria were: stable renal transplant function with a creatinine Ͻ4 mg/dl (creatinine clearance calculated with Modification of Diet in Renal Disease formula Ͼ20 ml/min), change of creatinine in the last year Ͻ0.5 mg/dl, no change of immunosuppressive therapy in the last three years, no apparent acute infection, and at least 60 months after renal transplantation. We studied 133 stable renal allograft recipients (58 female/75 male), mean time of 130 months (60 -306) after renal transplantation. Mean age of all patients was 56 years (20 -78), mean body mass index 24 kg/m 2 (18 -41). Immunosuppressive therapy consisted mainly of dual immunosuppression with low-dose steroids (2-8 mg/d) and CsA; in 21.8% of patients a triple immunosuppression with additional mycophenolic acid (22/133; 16.5%) and azathioprine (7/133; 5.3%) was used. None of the 133 patients had received induction therapy or antibody treatment for previous rejections.
Blood samples were drawn predose and two hr after oral intake of CsA at time of inclusion. Acute infection was excluded in all patients by the absence of clinical symptoms, negative urinary sediment and culture, normal high sensitive C-reactive protein and no detectable cytomegalovirus pp65 early antigen. Patients were monitored with respect to malignancy, previous recurrent viral and bacterial infections, and opportunistic infections occurring in the stable period at least 12 month after transplantation. Clinical data were obtained from patient's records.
Cyclosporine A Determination
All CsA blood levels were measured by enzyme multiplication immunoassay technique (Date-Behring) in the same laboratory.
Sample Preparation
Heparinized peripheral blood was stimulated with 1 ml of complete RPMI 1640 containing 100 ng/ml PMA and 5 g/ml ionomycin (Sigma) for three hr at 37°C. After red cell lysis with ACK buffer (0.15M ND4CI, 1.0 mM KHCO 3 ), leukocytes were lysed with 300 L of MagNA-Pure lysis buffer supplemented with additional 1% (w/v) dithiothreitol (RAS, Mannheim), and the sample was frozen at Ϫ70°C. After thawing, mRNA was isolated with the MagNA-Pure-LC device using the mRNA standard protocol for cells. The elution volume was set to 50 l. One aliquot of 8.2-l RNA was reverse transcribed using avian myeloblastosis virus reverse transcriptase (AMV-RT) and oligo-(dT) as a primer (First Strand cDNA synthesis kit; Roche) according to the manufacturer's protocol in a thermocycler. After termination of the cDNA synthesis, the reaction mix was diluted to a final volume of 500 l and stored at Ϫ20°C until polymerase chain reaction (PCR) analysis.
Quantitative Analysis of Gene Expression
The NFAT-regulated genes IL-2, IFN-␥, and GM-CSF have been identified as suitable genes for this assay in our previous study (14, 15) . Gene expression was quantified using real-time PCR with the LightCycler. Target sequences were amplified using commercially available LightCycler Primer Sets (Search-LC, Heidelberg) with the LightCycler FastStart DNA Sybr Green I Kit (Roche Diagnostics) according to the manufacturer's protocol. The transcript concentration for the measured genes was calculated from a virtual standard curve, obtained by plotting a known input concentration of a plasmid to the PCR cycle number at which the detected fluorescence intensity reaches a fixed value. mRNA input was normalized by a constant expression value of two housekeeping genes (␤-actin and cyclophilin B).
The residual gene expression after CsA intake was calculated as C2/C0*100, where C0 is the adjusted number of transcripts at CsA-predose level and C2 is the number of transcripts two hr after drug intake. For all three genes the residual expression was averaged and presented as "mean residual expression of NFAT-regulated genes."
In 82 patients without change of CsA dosage, repetitive measurements of NFAT regulated gene expression were performed in an interval between four weeks and 12 months.
Statistical Methods
Statistical analysis was performed using the SPSS 11.0 package (Chicago, IL). All statistical tests were two-tailed with a statistical significance level of 0.05. In the study population residual NFAT-regulated gene expression was not normally distributed, therefore non-parametric statistical tests were performed. The Mann-Whitney U test for comparison of sample medians was used, the chi-squared test for association between qualitative variables, Spearman's linear correlation coefficient for correlation between variables, and multivariate logistic regression analysis to determine the influence of several variables.
Results are expressed as percentages, means, and ranges. A target level for the residual NFAT regulated gene expression was defined by receiver operating curve (ROC) analysis of the combined infection and/or malignancy incidence.
RESULTS
Variability
In 82 cases, inhibition of NFAT-regulated gene expression was measured twice in an interval between four weeks to 12 months. Intraindividual variability in renal transplant patients on stable CsA immunosuppression was 9%. There was a strong correlation between the first and the second measurement (rϭ0.77, PϽ0.001). Interindividual variability in 31 patients with a daily CsA dose of 100 mg was 14%. The average variability of the reverse transcriptase polymerase chain reaction (RT-PCR) measurement was less than 11%.
Clinical Data
Mean serum creatinine of all patients was 1.4 (0.5-4.0) mg/dl. Mean CsA trough and two-hour blood levels in all 133 patients were 84 (25-181) and 521 (158 -1228) g/l, mean CsA peak/trough ratio was 6.7 (3.0 -18.5). Mean residual NFAT-regulated gene expression in all patients was 16 (2-50)% with a mean residual gene expression of IL-2 of 14% (1-54), IFN-␥ of 17% (2-55), and GM-CSF of 16% . Clinical data of renal transplant patients are given in Table 1 .
Univariate Analysis
A total of 58 of 133 patients (44%) had recurrent infectious complications or opportunistic infections (34 patients had urinary tract infections, two patients developed urosepsis, 24 patients had respiratory tract infections-predominantly viral infections assumed, four patients had pneumonia, seven patients showed cytomegaly viremia, one patient had recurrent erysipelas, and two patients developed repetitive herpes zoster). Patients with infections showed a significantly stronger inhibition of NFAT-regulated gene expression as compared to patients with no infections (13% (2-47) vs. 18% (2-50), Pϭ0.004, Table 2 , Fig. 1 ). Importantly, CsA trough and two-hour blood levels as well as the CsA peak/trough ratio were not statistically differ- By ROC analysis of the combined infection and/or malignancy incidence, a critical cutoff for the increased risk of infectious and malignant complications could be found at 15% of residual NFAT-regulated gene expression.
In 60.2% of all patients, residual NFAT-regulated gene expression was below 15%. Patients with a residual NFAT gene expression below the cutoff level of 15% (which means with a stronger immunosuppression) had significantly more infectious complications compared to patients with residual NFAT activity above 15% (53 vs. 29%, Pϭ0.005). In addition, patients with a residual NFAT-gene expression below 15% had significantly more malignancies compared to patients with residual NFAT activity above 15% (22 vs. 4%, Pϭ0.002). Only in three patients with malignancy was a residual NFATregulated gene expression above 20% observed. It is of particular interest that patients with nonskin malignancy (lung, breast, and uroepithelial cancer) had significantly lower residual NFAT-regulated gene expression compared to patients with skin cancer (4% (2-9) vs. 10% (4 -37), Pϭ0.02).
Biopsy-proven acute rejection episodes (one borderline, one BANFF I) were documented in two patients; residual NFAT-regulated gene expression in both patients was 47%. There was no significant correlation between residual NFATregulated gene expression and kidney transplant function (serum creatinine; rϭϪ0.136, Pϭ0.12).
Multivariate Analysis
A multiple regression analysis was performed including the following variables: age, follow-up after transplantation, kind of immunosuppression, CsA trough level, CsA 2-hour level, and residual NFAT regulated gene expression. Mean residual NFAT regulated gene expression was independently associated with recurrent infection (Rϭ0.229, betaϭϪ0.229, Pϭ0.009) and development of malignancies was significantly associated with age and NFAT regulated gene expression (Rϭ0.515, beta [alter]ϭ0.458, beta [NFAT regulated gene expression]ϭϪ0.205, PϽ0.001). Data for multivariate logistic regression analysis are given in Table 3 .
DISCUSSION
Immunosuppression with CsA has improved patient and transplant survival in the past 20 years. Although the immunosuppressive efficacy of CsA is well proven, there is no rationale with respect to the optimal dose of CsA particularly in the long-term treatment of allograft recipients. The bene- fits of CsA treatment decline in a considerable portion of patients due to severe side effects, such as malignancy, infection, and nephrotoxicity. It is therefore of particular importance to identify measurable parameters to assess the effect of CsA on the patient and the allograft survival. In general, measuring the trough level drug concentration is used to monitor CsA treatment. However, to achieve a more accurate CsA exposure, measurement of AUC for various durations (2 to 12 hr) was introduced but its clinical implementation is impracticable. Despite these efforts, side effects are not avoided and it is presumed that long-term allograft loss is mainly due to CsA toxicity. Several approaches have been undertaken to measure the biological impact of CsA-based immunosuppression. Calcineurin is a key component of T-cell activation and serves as the target of the CsA cyclophilin complex (16). Halloran et al. (11) demonstrated that the immunosuppressive action for CsA, when measured as inhibition of calcineurin activity in lymphocytes, is inversely correlated with CsA blood levels. In humans, peak CsA blood levels at one to two hours after oral CsA uptake resulted in a 70 to 96% inhibition of calcineurin, which was rapidly reversed when CsA blood levels came down to the trough levels (10, 11) . The results were further supported by the observation of Pai et al. (17) that a lower calcineurin activity resulted in a higher rate of graft versus host disease in bone marrow recipients.
Despite the increasing knowledge of the relationship between calcineurin activity and CsA levels, We recently introduced a precise, highly reproducible, and dynamic assay to measure the individual responsiveness of T-lymphocytes to CsA exposure in vivo. The assay is based of the quantitative analysis of IL-2, IFN-␥, and GM-CSF gene expression in PMA/ionomycin stimulated lymphocytes in whole blood samples of renal transplant recipients at CsA trough levels and two hr after oral uptake of CsA (14, 15) . The assay is not sensitive toward other commonly used immunosuppressive drugs such as corticosteroids, azathioprine, mycophenolic acid, or rapamycin. Therefore, the reduction of gene expression after two hr postoral uptake of CsA compared to the gene expression prior to CsA uptake reflects only the strength of CsA based immunosuppression. In order to make the test more powerful towards the interindividual variations in gene expression, a ratio between the values at peak and trough drug concentration was used. In addition, this opens the possibility to establish target values independent of the technical platform for gene expression analyses. The test can be performed semiautomated and highly standardized at relative low cost in a specialized laboratory. Overnight shipment of samples is possible. Results are available within one working day.
As we showed previously, the reduction of NFATdependent gene expression varies considerably between patients but is consistent within a given patient with a variability of 9% in the present study. It is of note that about 60% off all patients had a residual NFAT-regulated gene expression of less than 15%, which documents that the immune system in the majority of patients is more than necessary suppressed. In addition, the variability among patients reflects the individual immunosuppressive responsiveness to CsA. We studied patients beyond the fifth year after transplantation when the immunological risk is relative low compared to drug specific side effects such as malignancy and infections. In the present Categories: age (cutoff 65 years), follow-up after transplantation (60 -120 months, 121-180 months, Ͼ180 months), immunosuppression (CsA and steroids, CsA and MPA, CsA and azathioprine), CsA trough level (Ͻ50 g/l, 50 -99 g/l, 100 -149 g/l, Ͼ149 g/l), CsA two-hour level (Ͻ300 g/l, 300 -599 g/l, 600 -899 g/l, Ͼ899 g/l), and residual NFAT regulated gene expression (Ͻ10%, 10 -14%, 15-19%, Ͼ19%). study we detected a higher rate of malignancy, mainly nonmelanoma skin tumors (squamous and basal cell carcinomas), in patients with a significantly stronger reduction of NFAT gene expression compared to nontumor bearing longterm allograft recipients. There was no correlation between treatment for primary disease in patients with or without posttransplant malignancy. Furthermore, none of the patients with cancer was under cytotoxic induction therapy. The number of retransplants, both second and third, was not higher in tumor-bearing vs. nontumor-bearing patients. With respect to tumor genesis, we could demonstrate that a stronger inhibition (Ͻ90%) of NFAT gene expression two hr after CsA uptake is associated with a higher rate of malignancy, particularly skin cancer. It has been shown previously that patients on a high CsA-dose regimen are at increased risk for the development of cancer compared to patients on a low-dose regimen (19) . However, the patients in this study would match only the low dose group (median CsA trough concentration, 80 g/l; only three out of 133 patients had a CsA trough concentration above 150 g/l and none of those developed tumors). This might explain why we could not see in our study a correlation between malignancies and CsA trough levels or CsA peak/trough ratios.
Not only the rate of malignancy is augmented but also the frequency of infections is approximately doubled in patients with low residual NFAT expression two hr after CsA uptake. Patients with malignancy and/or infection received similar CsA doses per body weight. Patients with or without infections did not differ at CsA trough blood levels and CsA two hr blood levels, suggesting that this test better reflects the degree of immunosuppression in individual patients compared to drug concentration measurements.
Patients with a stronger inhibition of NFAT expression had a tendency to higher serum creatinine levels. To exclude an influence of transplant function on NFAT gene expression, we calculated the relative reduction of NFAT gene expression.
With the present study, we document the individual functional response of renal transplant recipients to CsA. A stronger inhibition of NFAT gene expression in the longterm follow-up is associated with a higher rate of cancer and infection. Patients at risk for these side effects can be identified and the CsA dose can be reduced accordingly while maintaining organ protective immunosuppression.
